Catch up on all the biggest pharma news to hit the industry last month, spanning from new acquisitions, insights on the NHS ...

A Blueprint Medicines Corp. patent describes new cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.

RGT-419B: Regor Therapeutics RGT-419B is a new generation of CDK inhibitor with an optimized kinase activity spectrum. The ...